Sumitomo Mitsui Trust Holdings, Inc. Avidity Biosciences, Inc. Transaction History
Sumitomo Mitsui Trust Holdings, Inc.
- $168 Billion
- Q3 2025
A detailed history of Sumitomo Mitsui Trust Holdings, Inc. transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Sumitomo Mitsui Trust Holdings, Inc. holds 7,755 shares of RNA stock, worth $540,445. This represents 0.0% of its overall portfolio holdings.
Number of Shares
7,755Holding current value
$540,445% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding RNA
# of Institutions
251Shares Held
119MCall Options Held
340KPut Options Held
145K-
Price T Rowe Associates Inc Baltimore, MD10.8MShares$753 Million0.03% of portfolio
-
Janus Henderson Group PLC London, X010.8MShares$751 Million0.16% of portfolio
-
Rtw Investments, LP New York, NY9.62MShares$670 Million4.2% of portfolio
-
Wellington Management Group LLP Boston, MA9.25MShares$645 Million0.05% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.25MShares$645 Million0.0% of portfolio
About Avidity Biosciences, Inc.
- Ticker RNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,127,000
- Market Cap $3.63B
- Description
- Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...